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Abstract
The efficient commitment of a specialized cell type from induced pluripotent stem cells (iPSCs) without contamination from
unknown substances is crucial to their use in clinical applications. Here, we propose that CD34+ progenitor cells, which
retain hematopoietic and endothelial cell potential, could be efficiently obtained from iPSCs derived from human bone
marrow mesenchymal stem cells (hBMMSC-iPSCs) with defined factors. By treatment with a cocktail containing mesodermal,
hematopoietic, and endothelial inducers (BMP4, SCF, and VEGF, respectively) for 5 days, hBMMSC-iPSCs expressed the
mesodermal transcription factors Brachyury and GATA-2 at higher levels than untreated groups (P,0.05). After culturing
with another hematopoietic and endothelial inducer cocktail, including SCF, Flt3L, VEGF and IL-3, for an additional 7–9 days,
CD34+ progenitor cells, which were undetectable in the initial iPSC cultures, reached nearly 20% of the total culture. This
was greater than the relative number of progenitor cells produced from human-skin-fibroblast-derived iPSCs (hFib-iPSCs) or
from the spontaneous differentiation groups (P,0.05), as assessed by flow cytometry analysis. These induced cells
expressed hematopoietic transcription factors TAL-1 and SCL. They developed into various hematopoietic colonies when
exposed to semisolid media with hematopoietic cytokines such as EPO and G-CSF. Hematopoietic cell lineages were
identified by phenotype analysis with Wright-Giemsa staining. The endothelial potential of the cells was also verified by the
confirmation of the formation of vascular tube-like structures and the expression of endothelial-specific markers CD31 and
VE-CADHERIN. Efficient induction of CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential with
defined factors, provides an opportunity to obtain patient-specific cells for iPSC therapy and a useful model for the study of
the mechanisms of hematopoiesis and drug screening.
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Introduction
CD34+ progenitor cells are used to treat many disorders, such
as incurable hematologic and lymphoid malignancies. However,
immune incompatibility, or gene disparity between recipients and
donors, causes graft-versus-host disease (GVHD) and other
transplant-related complications. These can cause graft failure or
even death [1]. Additionally, sources of transplantable CD34+
progenitor cells have been limited to bone marrow, umbilical cord
blood, and mobilized peripheral blood tissues. This makes it
difficult to obtain CD34+ progenitor cells in numbers sufficient to
reconstitute a normal blood system for an adult [2,3]. The high
risk of fatal complications and the quantity requirements for
CD34+ progenitor cells have prevented cell therapy from gaining
wide application. The study and establishment of efficient CD34+
progenitor cell induction systems are thus necessary [4,5].
Human embryonic stem cells (hESCs) are derived from the
inner cell mass of preimplantation embryos. These cells are
totipotent, capable of giving rise to all types of human cells and of
proliferating indefinitely in vitro under specific culture conditions.
Since the establishment of the first hESC line, people have been
immensely interested in using embryonic stem cells as an
alternative source of CD34+ progenitor cells for cell transplanta-
tion [6–13]. However, approaches using embryoid body (EB)
formation or co-culture with a feeder layer of mouse cells, such as
the OP9 stromal cell line or the S17 bone marrow cell line, are not
suitable for clinical applications. This is not only because of the
low differentiation efficiency, poorly defined induction compo-
nents, and contamination from animal sources, but also because of
the immune incompatibility and the ethical and legal restrictions
surrounding embryonic stem cell research [7].
The emerging of induced pluripotent stem cells (iPSCs) was a
breakthrough. Potentially patient-specific cells can be obtained
without the ethical concerns or immune rejection. They represent
a potentially unlimited source of functionally specific cell lineages
[14–17]. iPSCs have been demonstrated to be a viable alternative
to ESCs for generation of CD34+ progenitor cells, which is of
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study of disease mechanisms [10,18–21]. Studies performed by
Choi and his colleagues showed similar patterns of differentiation
potential between human iPSC lines and hESC lines, as
determined using an OP9 differentiation system [18]. Woods et
al. developed an optimized differentiation protocol using mouse
stromal cells with cytokines for the generation of hematopoietic
lineages from iPSCs [19]. However, the cells obtained from the
studies given above were contaminated with unidentified factors
from the mouse-derived cells. This is not in line with the crucial
step for cell-based therapy. Although several defined culture
conditions have been identified for directing human iPSCs
differentiation toward CD34+ progenitor cells, the overall efficacy
of these protocols remains low [20,21]. In one study, hiPSC-
derived CD34+ cells cannot develop into hematopoietic cells [21].
Better approaches for more efficient induction of CD34+
progenitor cells merit investigation. Hematopoietic potential is
strictly dependent on cellular signaling, as demonstrated by
Kennedy et al., and existing protocols for the efficient induction
of functional CD34+ progenitor cells appear to require treating
the differentiating cells with complex cocktails of factors that affect
the mesoderm, hematological, and endothelial cells [9,22–25].
Adult human bone marrow-derived mesenchymal stem cells
(hBMMSCs)aremultipotent,meaningthattheycandifferentiateinto
several lineages, such as osteoblasts, adipocytes, and chondrocytes
[26]. They are closely related to hematopoiesis. hBMMSCs have
immunosuppressive properties that make them interesting candidates
for cell-based therapy in organ transplantation. They are currently
used in regenerative medicine for tissue regeneration [27]. Although
hBMMSCs can be easily expanded in vitro,t h e yh a v el i m i t e dl i f e s p a n
and differentiation potentials in culture. This impedes further clinical
application of these cells. However, hBMMSC-derived iPSCs
(hBMMSC-iPSCs) may have greater potential in clinical applications
with indefinite passages. They are alsocapable of forming three germ
layers and are more immunologically compatible with patients than
hBMMSCs are. They also have other advantages over other types of
cell-derived iPSCs with respect to disease treatment [28]. Regarding
their epigenetic state in hematopoiesis, we propose that hBMMSCs
would be an excellent source of cells for the efficient generation of
functional CD34+ progenitor cells.
In this study, based on the reprogramming of hBMMSCs to
iPSCs by ectopic expression of four transcription factors OCT4,
SOX2, c-MYC, and KLF4, we demonstrated that functional
CD34+ progenitor cells retaining hematopoietic and endothelial
cell potential could be obtained more efficiently from hBMMSC-
iPSCs than from human-skin-fibroblast-derived iPSCs (hFib-
iPSCs) by sequential exposure to two sets of defined chemicals
and growth factors, which exert specific function on mesodermal,
hematological and endothelial cell signaling pathways, including
BMP4, SCF, Flt3L, VEGF, IL-3, and EPO. This induction system
for CD34+ progenitor cells is not contaminated by unidentified
substances because it does not involve mouse feeder layers or other
poorly defined induction components, providing an opportunity to
generate an unlimited number of human-leukocyte-antigen
matched (HLA-matched) transplantable cells and constitutes an
ideal cell model for the study of the mechanisms of hematopoiesis
and related diseases and drug screening.
Results
Generation and characterization of hBMMSC-iPSCs
We cultured hBMMSCs to passage 2–4 before reprogramming
them into iPSC. cDNAs encoding four transcription factors were
retrovirally transduced to hBMMSCs for iPSC generation. ESC-
like colonies were examined with standard characterization
procedures. AP staining showed that some ESC-like colonies
(Fig. 1A) exhibited comparatively strong AP activity (Fig. 1B),
whereas hBMMSCs had weak AP activity. No ESC-like colonies
were observed in hBMMSC cultures. Immunofluorescence assay
revealed that the colonies expressed pluripotent markers such as
OCT4 (Fig. 1C), NANOG (Fig. 1D), SSEA3 (Fig. 1E), and TRA-1-
81 (Fig. 1F). RT-PCR analysis verified the expression of pluripotent
genes such as Nanog, Oct4, Sox2, and Rex1 (Fig. 1G). The
differentiation potential of the colonies was determined with
spontaneous differentiation in vitro (Figs. 1H-I) and teratoma
formation in vivo (Figs. 1J–L). Taken together, the colonies had
features typical of ESC colonies in morphology, expression of
specific markers of pluripotency, and differentiation potential,
indicating that iPSCs had been generated from hBMMSCs.
iPSCs derived from human skin fibroblasts (hFib-iPSCs) were used
for parallel analysis. Because of the highly similar results, data for the
generation and characterization of hFib-iPSCs are not shown here.
Efficient commitment of hBMMSC-iPSCs into CD34+
progenitor cells by stepwise treatment with defined
factors
In this study, we followed a defined culture condition protocol
for CD34+ progenitor cell differentiation from hBMMSC-iPSCs.
We did so to evaluate the potential of iPSCs for therapeutic
applications. The culture scheme is given in Figure 2A. Factors
representing essential lineage-inducing factors for mesodermal,
hematopoietic, and endothelial cells, such as BMP4, PD98059,
Flt3L, SCF, and VEGF, were selected and divided into groups by
function, as shown in Figure 2B. In the initial induction step, the
culture for hBMMSC-iPSCs were depleted of the feeder layer and
bFGF, with the presence of BMP4, PD98059, Flt3L, SCF, and
VEGF for 5 days to induce cell aggregate formation. The results of
RT-PCR and immunofluorescence assays showed that Brachyury
and GATA-2 were up-regulated at this time. Higher expression
levels were observed in the groups treated with the inducer cocktail
than in the spontaneous differentiation groups (Figs. 2C-D). This
indicates that the factors employed here increased the potential of
hBMMSC-iPSC commitment to mesoderm cells. Immunofluores-
cence assays confirmed that the transcription factor GATA-2 was
up-regulated and that efficiency was more pronounced in
hBMMSC-iPSC groups treated with the cocktail than in the
spontaneous differentiation groups. However, the expression of the
pluripotent marker OCT4 was similar in both groups (Fig. 2E).
After treatment for another 7–9 days with the cocktail containing
SCF, Flt3L, VEGF, bFGF, IL-3, and IL-6, the mixed population
displayed a series of changes. CD34+progenitor cells, undetectablein
undifferentiated hBMMSC-iPSCs, increased in number, as assessed
by flow cytometry analysis. The proportion reached 19.5864.37%
(mean 6 S D ,n=6 ,F i g .3 A ) ,h i g h e rt h a nt h a to b s e r v e di np a r a l l e l
hFib-iPSCs (13.2063.14%, mean 6 S D ,n=6 ,F i g .3 B ) ,a b o u t1 0
fold that observed in spontaneously differentiated hBMMSC-iPSCs
(2.1061.47%, mean 6 S D ,n=4 ,F i g .3 C ) ,a n da b o u t2 0f o l dt h a to f
spontaneously differentiated hFib-iPSCs (1.3062.56%, mean 6 SD,
n=4, Fig. 3D) (P,0.05). CD34+ progenitor cells were then isolated
and enriched from the induced population by magnetic procedure
and the purity reached more than 90% (Figs. 3E-F). The different
replicates were derived from independent reprogramming cells.
Differentiation of hBMMSC-iPSCs was confirmed by the down
expression of pluripotency markers, Oct4 and Sox2 by flow
cytometry, as shown in Figures 3G-J.
Additionally, we separated the chemically induced cells into
CD34+ and CD34- subsets and demonstrated that the former only
had detectable CD34 transcripts (Fig. 3K).
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34321Figure 1. Generation and characterization of iPSCs from hBMMSCs. Representative hBMMSC-iPSCs colonies (A) and AP staining (B). (C-F)
Immunoassay of hBMMSC-iPSC colonies expressing ESC specific markers as OCT4 (C), NANOG (D), TRA-1-81 (E) and SSEA-3 (F). 4, 6-Diamidino-2-
phenylindole (DAPI) staining was used to reveal the nuclei. Scale bar, 100 mm. (G) RT-PCR analysis of endogenous pluripotent gene mRNA expression
in hBMMSC-iPSCs. Total RNA was isolated from hBMMSC-iPSCs, ESCs and hBMMSCs. (H-L) Pluripotency assay of hBMMSC-iPSCs. EBs was formed (H)
and spontaneously differentiated into many types of cells during the in vitro potential assay (I). (J-L) Hematoxylin and Eosin staining of teratoma
sections from hBMMSC-iPSCs. 1610
7 of hBMMSC-iPSCs were injected subcutaneously into limbs of NOD/SCID mice. Teratomas were obtained after
8–10 weeks. Three germ layer as ectoderm, neural-like tissue (J); mesoderm, adipose tissue (K) and endoderm, intestinal-like epithelium (L) were
observed.
doi:10.1371/journal.pone.0034321.g001
Figure 2. Exploration the potential of hBMMSC-iPSCs into CD34+ progenitor cells with the defined factors. (A) Schematic of CD34+
progenitor cell differentiation protocol for the study. (B) Protocol for the chosen defined factors, divided into groups according to their function, to
direct hBMMSC-iPSCs to CD34+ progenitor cells, and then to hematopoietic and endothelial cells. (C-D) Enhanced expression of mesoderm
transcription factor Brachyury and GATA-2 was detected in factor-treated hBMMSC-iPSCs, compared to the spontaneous differentiation groups by RT-
PCR (C) and fluorescence intensity (D) assay after the differentiation for 5 days. The values were the mean 6 SD of 3 independent experiments. (E)
Immunoassay revealed that the hematopoietic transcription factor GATA-2 was up-regulated after factor treatment for 5 days and it was more
efficient in hBMMSC-iPSC groups treated with the factors than in the spontaneous groups (control). The expression of the plutipotent marker Oct4
was similar between two groups. Scale bar, 100 mm.
doi:10.1371/journal.pone.0034321.g002
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differentiation of hBMMSC-iPSCs
Flow cytometry and RT-PCR assays were used to detect the
dynamic course of hematopoietic differentiation of hBMMSC-
iPSCs via treatment with the cocktails. The results of flow
cytometry analysis were shown in figure 4A-D. Undifferentiated
hBMMSC-iPSCs expressed no CD34 or CD45 (Fig. 4A), and a
very low percentage of CD34+ cells, but no CD45+ cells were
detected after induction for 5 days (Fig. 4B). After treatment with
the following cocktail for another 7–9 days, the number of CD34+
increased significantly relative to the total number of cells.
However, few CD45+ cells were obtained at this stage (Fig. 4C).
As the hematopoietic induction continued, samples obtained from
the CFU assay developed a subpopulation of CD34+CD45+ cells,
and the percentage increased until about 24 days of culture
Figure 3. Efficient commitment of hBMMSC-iPSCs into CD34+ progenitor cells by treatment with the defined factors. CD34+
progenitor cells were identified by flow cytometry analysis in the groups. Differentiated hBMMSC-iPSCs treated with the factors produced about 20%
proportion of CD34+ progenitor cells (A), higher than that of nearly 13% from hFib-iPSCs by parallel performance (B). However, the efficiency for the
spontaneous differentiation groups was low. The proportion in hBMMSC-iPSCs treated with no factor was nearly 2% (C) and it was much lower in
hFib-iPSCs of nearly 1% (D). The data demonstrated that the defined factors employed here efficiently improved the efficient differentiation of CD34+
progenitor cells from iPSCs, and iPSCs derived from hBMMSCs was more efficient to produce CD34+ progenitor cells than those derived from human
fibroblasts. The enriched CD34+ progenitor cells were analyzed from hBMMSC-iPSC versus hFib-iPSC differentiation systems by flow cytometry (E-F).
(G-J) Flow cytometry analysis demonstrated that the expression of Oct4 (G and I) and Sox2 (H and J) was down regulated at day 14 after the
differentiation. (K) The chemically induced cells were separated into CD34+ and CD34- subsets and the former only had detectable CD34 transcripts.
doi:10.1371/journal.pone.0034321.g003
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development of more mature hematopoietic cells. The result of the
hematologic differentiation of hBMMSC-iPSCs shown here
suggests that the hematopoiesis was a dynamic process. RT-
PCR and Image J analysis demonstrated that the pluripotent
marker Oct4 continued to be down-regulated and the hemato-
poietic special genes TAL-1 and SCL were sustainably up-
regulated during the process (Figs. 4E-F). At day 14 after the
differentiation, the expression of TAL-1 and SCL reached a
considerable level while the expression of Oct4 was not detected
(Figs. 4E-F). The kinetics of CD34+ cells from hBMMSC-iPSCs
versus hFib-iPSCs treated with the cocktails was also detected as
shown in figure 4G, indicating that the efficiency of hematopoietic
differentiation from hBMMSC-iPSCs was more efficient than that
from hFib-iPSCs.
Differentiation of hBMMSC-iPSC-derived CD34+
progenitor cells into hematopoietic cell lineages
CD34+ progenitor cells were isolated to determine their CFU
potential in methylcellulose and in hematopoietic cytokines
including SCF, VEGF, TPO, EPO, IL-3, IL-6, and GM-CSF.
CFUs were enumerated 14 days later and the number of colonies
in the hBMMSC-iPSC groups is higher than that in the hFib-iPSC
groups (Fig. 5A).
Various CFUs were identified in the culture after 10–14 days.
These CFUs included burst-forming units of erythroid lineages
(BFU-E) (Fig. 5B), small colonies of erythroid cells (CFU-E)
(Fig. 5C), CFU-granulocytes and macrophages (CFU-GM)
(Fig. 5D), CFU-granulocytes, erythroid cells, macrophages, and
megakaryocytes (CFU-GEMM) (Fig. 5E), and CFU-granulocytes
(CFU-G) (Fig. 5F). Hematopoietic cell lineages including erythroid
cells, granulocytes, megakaryocytes, and macrophages were
characterized using Wright-Giemsa staining (Figs. 5G–I). Addi-
tionally, representative colony morphologies including BFU-E
(Fig. 6A), CFU-E (Fig. 6B), CFU-GM (Fig. 6C), CFU-GEMM
(Fig. 6D), CFU-G (Fig. 6E), and CFU-M (Fig. 6F) from hFib-
iPSC-derived CD34+ cells were shown as control.
Differentiation of hBMMSC-iPSC-derived CD34+
progenitor cells into endothelial cells
In this study, hBMMSC-iPSC-derived CD34+ progenitor cells
were differentiated into endothelial cells in endothelial cell growth
medium-2 (EGM-2). Immunoassay results showed that some
hBMMSC-iPSC-derived CD34+ progenitor cells could differenti-
ate into endothelial cells, as determined by the expression of
endothelial cell-specific proteins, including CD31 and VE-
CADHERIN (Figs. 5J and 5K). These cells formed vascular-like
structures on Matrigel when the cultures were supplemented with
VEGF-A (Fig. 5L).
Figure 4. Kinetic expression of the hematopoietic and pluripotent genes during hBMMSC-iPSC commitment to CD34+ progenitor
cells, and then to hematopoietic cells. (A-D) Kinetic expression of CD34+ and CD45+ during the hematopoietic cell differentiation of hBMMSC-
iPSCs with flow cytometry analysis. Undifferentiated hBMMSC-iPSCs expressed no CD34 or CD45 (A). After treatment with the cocktail containing
mesodermal, hematopoietic, and endothelial inducers for 5 days, hBMMSC-iPSCs expressed about 5% percentage of CD34+ but few CD45+ cells (B).
After culturing with the following hematopoietic and endothelial inducer cocktail for additional 7–9 days, the proportion of CD34+ population
increased to nearly 20% and a few CD45+ cells were obtained at this stage (C). In hematopoietic potential assay of CD34+ progenitor cells, about 5%
population of CD34+CD45+ cells were developed from the CFU assay, and the percentage of CD45+ cells increased to about 25% during the
differentiation culture (D). (E-F) Dynamically relative expression of the pluripotent marker Oct4 and the hematopoietic cell markers TAL-1, SCL during
hBMMSC-iPSC commitment to CD34+ progenitor cells, and then to hematopoietic cells by RT-PCR (E) and fluorescence intensity (F) assay in the
differentiation culture. The values were the mean 6 SD of 3 independent experiments. (G) Kinetics of CD34+ cells during hematopoietic
differentiation of hBMMSC-iPSCs versus hFib-iPSCs treated with the inducers.
doi:10.1371/journal.pone.0034321.g004
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Human somatic cells can be reprogrammed into a pluripotent
state by ectopic expression of pluripotent transcription factors.
This process provides a new source of cells with the capacity of
indefinite proliferation and patient-matched HLA specificity
suitable for cell-based therapy, eliminating the risk of GVHD
and the need for immunosuppressive drugs or immunomodulatory
protocols in cell transplantation [14–17].
Efficient commitment to functional CD34+ progenitor cells
from human iPSC is crucial for the clinical application of iPSC.
Although previous studies have demonstrated that pluripotent cells
can be differentiated into hematopoietic cells using either stromal
cell co-culture or EB–based systems [9,23–25,29], the induction
efficacy and cellular function of CD34+ progenitor cells from
ESCs or iPSCs vary greatly with the different protocols, due to
differences in cell derivation methods, cytokine composition, and
types of feeder support. In the present study, the spontaneous
differentiation approach involving EB formation was found to be
Figure 5. Hematopoietic and endothelial cell potential assay of CD34+ progenitor cells obtained from differentiated hBMMSC-
iPSCs. (A-I) Hematopoietic CFU formation and hematopoietic lineages assay for the potential of CD34+ progenitor cells. (A) Measurement for CFU
potential of CD34+ cells derived from hBMMSC-iPSCs compared to that from hFib-iPSCs. (B-F) Various types of CFUs were observed with a reversed
telescope as BFU-E (B), CFU-E (C), CFU-GM (D), CFU-GEMM (E) and CFU-G (F) when CD34+ progenitor cells derived from hBMMSC-iPSCs were seeded
into CFU forming culture system to assess the short-term differentiation capabilities of hematopoietic progenitors. (G-I) Morphologies of the
hematopoietic lineages derived from CFU culture of CD34+ progenitor cell commitment to hematopoietic cells observed with a reversed telescope
(Olympus), including erythroid from BFU-E (G), granulocyte from CFU-G (H) and macrophage, granulocyte, erythroid, megakaryocyte from CFU-GEMM
(I). (J-L) Analysis of endothelial cell potential of CD34+ progenitor cells derived from hBMMSC-iPSCs. Some of CD34+ progenitor cells cultured with
EGM-2 were positive to CD31 (J) and VE-CADHERIN (K). When treated with VEGF-A on Matrigel for 3 days, vascular-like structures were photographed
(L).
doi:10.1371/journal.pone.0034321.g005
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high risk of contamination from unidentified factors [18,19].
Several other studies have reported that hematopoietic progenitors
can be generated from iPSCs in fully defined conditions [20,21].
However, these reports note that overall efficacy remains low and
hiPSC-derived CD34+ cells cannot form hematopoietic colonies
[21].
In this study, we selected hBMMSC-derived iPSCs to produce
CD34+ progenitor cells because BMMSC have several advantages
over other cell types: they provide an environment for hemato-
poiesis, their epigenetic state might favor hematopoiesis, and they
have been widely used in clinics for many years. Meanwhile, we
selected the defined factors that can specifically promote the
functions of mesodermal, hematological, and endothelial cells,
including BMP4, SCF, Flt3L, VEGF, IL-3, etc. We then used
these factors to induce the differentiation of hBMMSC-iPSC into
CD34+ progenitor cells. Factors that can affect mesoderm
signaling pathways, such as BMP4 and PD98059, were used to
enhance mesoderm differentiation and to initiate the production of
CD34+ progenitor cells [20,21,23,30]. Flt3L, SCF, and VEGF are
early-acting hematopoietic and endothelial cell factors [20,21,30–
34]. They were used here to activate early hematologic and
endothelial signaling pathways in the differentiation system. After
iPSCs were cultured for 5 days in the differentiation medium, a
higher percentage of mesoderm cells were induced in the presence
of the first inducer cocktail, including BMP4 and SCF, than
without the cocktail supplement (P,0.05). These mesoderm cells
were then induced to become CD34+ progenitor cells by culturing
with the second cocktail, which include SCF and IL-3, for another
7–9 days. Cellular morphology and the expression of the
hematopoietic transcription factors TAL-1 and SCL in these cells
confirmed that they are hematopoietic cells. The differentiated
hBMMSC-iPSCs contained nearly 20% of CD34+ progenitor
cells, more than that from hFib-iPSCs (nearly 13%) or the
spontaneous differentiation groups (P,0.05). These results dem-
onstrate that the factors employed here could efficiently differen-
tiate iPSCs into CD34+ progenitor cells, and CD34+ progenitor
cells could be more efficiently generated from hBMMSC-iPSCs
than from hFib-iPSCs.
We further verified that the CD34+ cell population had
hematopoietic and endothelial cell potential. RT-PCR showed
that the differentiation population expressed hematopoietic
transcription factors TAL-1 and SCL. When these cells were
subjected to the hematopoietic colony-forming cell assay, various
hematopoietic CFU colonies were formed. These included CFU-
E, BFU-E, CFU-G, CFU-GM, and CFU-GEMM, indicating that
these CD34+ cells are truly multipotent, with the ability to form all
types of blood cells. The number of CFUs derived from
hBMMSC-iPSC groups was greater than that from hFib-iPSCs.
One possible explanation is that hBMMSC-iPSCs might retain
their epigenetic memory. Furthermore, the time for CFUs
identification was various [35–37], and the reason may be that
the cells and the culture system are different. In our study, we
observed BFU-E and CFU-E forming with small size during the
first week and the colonies would grow following the next days. We
identified various CFUs in the culture during 10–14 days and
enumerated CFUs at day 14. CD34+ progenitor cells were also
found to have endothelial potential. When cultured in endothelial
cell medium, these cells produced CD31 and VE-CADHERIN,
which were endothelial specific adhesion molecules. Formation of
vascular-like structures in matrigels further confirmed their
endothelial identity.
During the hematopoietic commitment of hBMMSC-iPSCs, the
pluripotent gene Oct4 continued to be down-regulated and its
expression completely vanished at day 14 after induction.
However, the expression of the hematologic transcription factors
TAL-1 and SCL underwent a dynamic process, showing up-
regulation at the initial induction stage and then gradual down-
regulation after CD34+ progenitor cell commitment to CFU
formation. The down-regulation and disappearance of Oct4
expression seems contradictory to the reports of direct conversion
of human fibroblasts to multilineage blood progenitors by ectopic
expression of Oct4 [38]. One explanation is that Oct4 activation
of hematopoietic transcription factors in only a specific stage of
early hematopoiesis. Another explanation is that other POU
domain proteins, such as OCT1 and OCT2, might have a
redundant role in hematopoietic fate conversion [38]. However,
the mechanism merits further study.
Seiler et al. reported that compare to fibroblast-derived iPSCs,
iPSCs generated from mouse bone marrow hematopoietic
progenitor cells have severely reduced capacity to differentiate
from mesodermal to hematopoietic progenitor cells [39]. The
authors found that elevated expression of the ectopic transcription
factors Sox-2, Oct-4 and Klf4 inhibited the differentiation of iPSC
to hematopoietic progenitor cells. To generate iPSCs, they used
the pMY vectors, which retrovirally transduced the cells and
caused irreversible ectopic expression of the transduced genes. To
circumvent this problem, we used the pMXs-based retroviral
vectors, and at day 14 after the differentiation, we could no longer
detect the expression of Sox-2 and Oct-4.
Figure 6. Representative colony morphologies from hFib-iPSC-
derived CD34+ cells. CD34+ progenitor cells obtained from hFib-
iPSCs were cultured in CFU forming culture system for hematopoietic
CFU formation. Various types of CFUs were observed as BFU-E (A), CFU-
E (B), CFU-GM (C), CFU-GEMM (D), CFU-G (E), and CFU-M (F).
doi:10.1371/journal.pone.0034321.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34321In conclusion, CD34+ progenitor cells, retaining hematopoietic
and endothelial cell potential, can be efficiently induced from
hBMMSC-iPSCs with a two-step, fully defined culture system.
Additionally, hBMMSC-derived iPSCs were found to produce
CD34+ progenitor cells more efficiently than human-skin-
fibroblast-derived iPSCs did. This system provides a novel method
of generating personalized CD34+ progenitor cells, which can
potentially be used for cellular therapy, drug screening, and
hematologic disease study. However, to determine the real biology
and safety of iPSC-derived hematopoietic cells, their in vivo
function should be carried out in the future. There might be a long
way to go for reprogrammed cell therapeutic use.
Materials and Methods
Cell culture
hBMMSCs were used as target cells for reprogramming.
hBMMSCs were recovered from liquid nitrogen which were
frozen by our team members and saved in our laboratory. The
characteristics of these cells have been identified [40]. hBMMSCs
were cultured in a flask at a density of 10
7 cells per 75 cm
2 in
DMEM (GIBCO) supplemented with 10% fetal bovine serum
(FBS) (GIBCO), 100 U/ml ampicillin, and 100 U/ml streptomy-
cin (GIBCO) at 37uCi n5 %C O 2 atmosphere. hBMMSCs were
split with 0.25% trypsin/ethylene diaminetetraacetic acid (trypsin-
EDTA, Invitrogen) when cells reached 90% confluence.
hBMMSCs at passages 2–4 were used for iPSC generation.
Generation of iPSCs from hBMMSCs
Retroviral supernatants were prepared as described by
Yamanaka S et al. with some modifications [16]. Briefly, each
pMXs-based retroviral vector containing reprogramming factors –
hOct4, –hSox2, –hcMyc, and –hKlf4 (Addgene: http://www.
addgene.org) was used with a mixture of two helper plasmids:
pCMV-G and pCMV-GP. Two micromoles of VPA (Sigma) and
25 mg/ml Vc (Sigma) were supplemented to improve efficiency.
Cultures were maintained at 37uC, 5% CO2 with daily medium
changes. VPA was supplemented for 7 days and Vc was added
until colonies were picked for expansion. During the reprogram-
ming, colonies were observed daily with a reversed microscope
(Olympus). Based on cell morphology at 15–18 days after the
initial infection, colonies were picked for expansion culture on
mitomycin-C-treated mouse embryonic fibroblasts (CF1, SiDan-
Sai Biotechnology Co. , Ltd, Shanghai, China) in hESC culture
medium consisting of 80% DMEM/F12 (Invitrogen), 20%
knockout serum replacement (KSR) (Invitrogen), 1 mM L-
glutamine (Invitrogen), 1% non-essential amino acids (NEAA)
(Invitrogen), 0.1 mM b-mercaptoethanol (Invitrogen), and 4 ng/
ml basic fibroblast growth factor (bFGF) (Invitrogen). iPSCs were
passaged by 1 mg/ml collagenase IV (Invitrogen). The medium
was changed every day. Colonies expanded up to 10 passages were
used for determination of iPSC characteristics. Alkaline phospha-
tase (AP) staining was performed with an alkaline phosphatase
detection kit (Millipore) according to the manufacturer’s instruc-
tions. Differentiation potential in vitro and in vivo analysis was
carried out as described by Yu et al. [15].
Human-skin-fibroblast-derived iPSCs (hFib-iPSCs) served as
control groups in the assessment of the efficiency of the CD34+
progenitor cells under the same treatment conditions. hFib-iPSCs
were generated from human skin fibroblasts using the same
protocol, given above.
Immunofluorescence assays
For analysis of immunofluorescence, cells were fixed with 4%
paraformaldehyde at room temperature for 15 minutes. When
nuclear proteins were detected, cells were permeabilized with
0.1% Triton X-100 in PBS and then blocked with normal goat
serum for 1 hour at room temperature. Staining was performed
using the following antibodies (Santa Cruz): anti-OCT4, anti-
NANOG, anti-SSEA3, anti-TRA-1-81, anti-GATA-2, anti-CD31,
and anti-VE-CADHERIN overnight at 4uC. Then the cells were
washed several times with PBST (0.1% Tween-20 in PBS).
Secondary antibodies conjugated to FITC or Cy3 (Boster) were
used for fluorescence detection followed by counterstaining with
DAPI (Boster) to reveal nuclei. Images were obtained using a
confocal microscope (LSM 510 Meta, Zeiss).
RT-PCR analysis
The primer sets for reverse transcription PCR analysis of
endogenous pluripotent genes and hematopoietic commitment
gene expression were designed as shown in Table 1 using Primer
Premier 5 software. Total RNA was prepared using TRIzol
(Invitrogen) according to the manufacturer’s protocol, and then
used for cDNA synthesis. First-strand cDNA was synthesized with
Superscript III First Strand Synthesis SuperMix (Invitrogen) for
quantitative reverse transcription PCR. GAPDH was used as an
endogenous control. PCR was performed in a 20 ml mixture
containing 16 PCR buffer, 0.5 U of Taq DNA polymerase,
0.2 mM each of dNTP and 1.5 mM MgCl2, 0.2 mM of each
primer, and 2 ml of each RT product as a template. The following
program was carried out: initial denaturation for 4 min at 94uC,
35 cycles of 94uC for 15 s, then 35 s at temperatures specific to
each transcript (51uC for Nanog and Rex-1; 53uC for GAPDH,
Brachyury, and TAL-1; 55uC for Oct4; 58uC for GATA-2; 60uC
for SCL ; 68uC for Sox2), and 72uC for 1 min. This was followed
by 72uC for 10 min. cDNA from hBMMSCs was used as a
negative control. cDNA from human ESC line H1 served as a
positive control. Image J software was used to measure the
intensity to determine the influence of chemical treatment on
hBMMSC-iPSC commitment to CD34+ progenitor cells. The
reactions were measured in triplicate.
EB formation of hBMMSC-iPSCs by defined chemicals and
growth factors
At confluence, undifferentiated iPSCs were treated with
collagenase IV and then cultured for cell aggregate formation
with the feeder layer and bFGF depleted from the culture system.
The cells were fed with the differentiation medium (KnockOut
DMEM, 2 mM GlutaMAX,1% NEAA, 0.1 mM b-mercaptoeth-
anol, 50 U/mL penicillin, 50 mg/mL streptomycin) and the first
group of the defined factors, including 20 ng/mL bone morpho-
genetic protein 4 (BMP4), 50 mM PD98059, 300 ng/mL stem cell
factor (SCF), 300 ng/mL FMS-like tyrosine kinase 3 ligand (Flt3L)
(all from R&D Systems), and 100 ng/mL vascular endothelial
growth factor (VEGF) (StemCell). The spontaneous differentiation
cultures treated with differentiation medium alone served as
controls. After about 5 days of culture, the populations of small
embryoid bodies were generated and harvested. Some of the
embryoid bodies were collected to determine the expression of the
pluripotent marker OCT4 and the mesodermal transcription
factors Brachyury and GATA-2 by immunofluorescence and RT-
PCR assays. The rest of the cells were prepared for CD34+
progenitor cell commitment using the following growth factor
cocktail treatment or by allowing cells to spontaneously differen-
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CD34+ progenitor cell differentiation by growth factor
treatment
For CD34+ progenitor cell differentiation, hBMMSC-iPSCs
were cultured with the differentiation medium supplemented with
BMP4, PD98059, SCF, Flt3L, and VEGF for 5 days. They were
then dissociated into single-cell suspensions using collegenase IV
followed by 0.25% trypsin-EDTA and plated on low-cluster plates
in StemPro-34 (StemCell) supplemented with the second set of
growth factors: 300 ng/mL SCF, 300 ng/mL Flt3L, 100 ng/mL
VEGF, 5 ng/mL bFGF, 20 ng/mL interleukin-3 (IL-3) (StemCell)
and 20 ng/mL interleukin-6 (IL-6) (StemCell) for an additional 7–
9 days to induce CD34+ progenitor cell formation. The cells were
then prepared for further characterization by flow cytometry
analysis for CD34+ progenitor cells and CD45+ cells and by RT-
PCR for the expression of the pluripotent marker OCT4 and
hematopoietic transcription factors TAL-1 and SCL. Several other
assays were performed to demonstrate induced cell commitment to
hematopoietic and endothelial cells.
Regarding assessment of the efficiency of iPSC spontaneous
differentiation to CD34+ progenitor cells, EBs obtained from the
differentiation medium alone were cultured on low-cluster plates
in StemPro-34 supplemented with no chemicals for an additional
7–9 days, and then the cells were prepared for analysis of CD34+
progenitor cells by flow cytometry.
Flow cytometry analysis
Flow cytometry analysis was performed as described by
Thomson with some modifications [24]. Briefly, the differentiated
cell mixtures were washed in Ca
2+- and Mg
2+-free PBS and
dissociated with 1 mg/ml collagenase IV and 0.05% trypsin/
0.53 mM EDTA supplemented with 1% mouse serum (GIBCO)
for 5–10 min. Cell clumps were removed from the dissociated cells
by filtering the mixture through 40 mm cell strainers. The single
cell suspension (1610
6) was prepared in PBS-1% FBS containing
0.1% sodium azide, and labeled with either isotype control or
antigen-specific antibodies. Directly conjugated isotype control
antibodies IgG1-FITC and IgG1-phycoerythrin (PE) (BD) were
used to determine the autofluorescence background of the cells. As
for nuclear proteins of Oct4 and Sox2, the cells are fixed and
treated with 0.1% Triton X-100 before staining. The following
antibodies were used: CD34-PE, CD45-FITC, Oct4-FITC, and
Sox2-FITC (all purchased from BD). Dead cells were stained with
the seven-aminoactinomycin (7-AAD) staining solution (BD), and
excluded from the analysis. The analysis of antibody-labeled cells
was performed using a BD FACScalibur instrument (BD).The data
were analyzed using FlowJo Version 7.2.5 software. Independent
experiments for flow cytometry assays were performed in
triplicate.
CD34+ progenitor cell enrichment
CD34+ progenitor cells were collected using CD34 MicroBead
Kit (Milteneyi Biotech) on MiniMACS device (Milteneyi Biotech)
according to the manufacturer’s instructions.
Colony-forming unit assay
Colony-forming unit (CFU) assay was performed to analyze the
hematopoietic colony-forming potential of CD34+ progenitor cells
isolated from the differentiation system.
The cells were dissociated with 0.25% trypsin/EDTA, dispersed
by passaging them through a 20-gauge needle, and then
transferred at 5000 cells per ml onto a low adherent dish with
IMDM containing 9% MethoCult supplemented with 0.1 mM 2-
mercaptoethanol, 2 mM GlutaMAX, and the following cytokines:
100 ng/mL SCF, 100 ng/mL VEGF, 3 U/mL thrombopoietin
(TPO), 3 U/mL erythropoietin (EPO), 20 ng/mL IL-3, 20 ng/
mL IL-6, 50 ng/mL granulocyte colony-stimulating factor (G-
CSF), and 50 ng/mL granulocyte-macrophage colony-stimulating
factor (GM-CSF) (all from StemCell) for a further 12–14 days to
promote hematopoietic specification. The progenitors formed
hematopoietic colonies. CFUs were determined and enumerated
at days 22 to 26 after initial iPSC differentiation by colony shape,
cell size, and the extent of visible cell content. Lineage assignment
was confirmed with Wright-Giemsa staining within the CFU
colonies by morphological analysis.
Western blot
Cell extracts were prepared using RIPA Lysis and Extraction
Buffer (Thermo). The total protein concentration was analyzed
with Bio-Rad protein assay (Biorad) per the manufacturer’s
instructions. Forty micrograms of total proteins were prepared to
standard western blot procedure followed by immunodetection
with an anti-human CD34 antibody (santa cruz). B-actin was used
as an internal control.
Endothelial cell induction and vascular tube-like structure
formation
For the assay of endothelial cell potential, CD34+ progenitor
cells were plated onto fibronectin-coated (Invitrogen) plates in
endothelial cell growth medium EGM-2 (BD Falcon). To
determine the expression of CD31 and VE-CADHERIN by
immunofluorescence assay, the endothelial cultures were fixed in
4% paraformaldehyde, permeabilized with 0.1% Triton X-100,
and blocked with goat serum. Samples were labeled with mouse
anti-human anti-CD31 (Santa Cruz) or mouse anti-human anti-
VE-CADHERIN (Santa Cruz) followed by treatment with FITC-
conjugated anti-mouse-IgG (Boster). They were then examined
using a confocal microscope (LSM 510 Meta, Zeiss).
For the assay of the formation of vascular tube-like structures,
5610
5 CD34+ progenitor cells in a 6-well plate, derived from the
differentiation system were incubated on Matrigel matrix (BD
Biosciences) and solidified for 1 hour at 37uC in EGM-2
supplemented with 40 ng/ml vascular endothelial growth factor-
A (VEGF-A) for 3 days. The vascular tube-like structures were
photographed with an inverted microscope (Nikon).
Table 1. Primer sets for the pluripotent genes, hematopoietic
commitment genes by RT-PCR.
Genes Sequence (59 to 39) F Sequence (59 to 39)R
Oct4 TTCAGCCAAACGACCATC GGAAAGGGACCGAGGAGTA
Sox2 AAACAGCCCGGACCGCGTCAA TCGCAGCCGCTTAGCCTCGT
Nanog CCTATGCCTGTGATTTG AGAAGTGGGTTGTTTGC
Rex1 GGCAAAGACAAGACACC GCAAATTCTGCGAGCT
GAPDH AAGGTCGGAGTCAACGG GGAAGATGGTGATGGGATT
Brachyury TGAGCCTCGAATCCACAT GGGCACCTCCAAACTGA
GATA-2 GGCGTCAAGTACCAGGTGT GGTCGGTTCTGCCCATTC
SCL ATGCCTTCCCTATGTTCACCA CCA TGAAGATAGCCGCACAACTT TGG
TAL-1 TTGTGCGGCGTATCTTC CAGGGTCCTTGCCAGTC
doi:10.1371/journal.pone.0034321.t001
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Statistical analyses were performed with SPSS software (version
13.0). P values less than 0.05 were accepted as statistically
significant.
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